Bristol-Myers Squibb

2012 Preview: Cancer Immunotherapy Catalysts
Seeking Alpha
Thu, 12/15/11 - 12:08 pm
cancer
Antigenics
Amgen
Bristol-Myers Squibb
Celgene
Dendreon
Generex
Merck KGaA
GSK
Idera Pharmaceuticals
NewLink Genetics
Novartis
Roche
Oncothyreon
Transgene
Vical
Bristol-Myers and NeurOp extend deal through 2012
Yahoo/AP
Wed, 12/14/11 - 01:04 pm
Bristol-Myers Squibb
NeurOp
neuropathic pain
9 Biotech Companies With FDA Approval Decision Dates In Q1 2012
Seeking Alpha
Mon, 12/12/11 - 11:14 am
FDA
Fentanyl SL
INSYS Therapeutics
Dapagliflozin
Bristol-Myers Squibb
Prochieve
Columbia Laboratories
Discovery Labs
Surfaxin
NeurogesX
Qutenza
Curis
Roche
vismodegib
Chelsea Therapeutics
Northera
ONYX Pharmaceuticals
Carfilzomib
Bristol-Myers Presents Data
Yahoo/Zacks
Sat, 12/10/11 - 12:56 pm
Bristol-Myers Squibb
AstraZeneca
diabetes
Dapagliflozin
glimepiride
Merck
NovoNordisk
Future Dividend Growth In Bristol-Myers Squibb Will Be Weak
Seeking Alpha
Fri, 12/9/11 - 09:41 am
dividends
Bristol-Myers Squibb
6 Buffett-Friendly Pharmaceutical Stocks
Seeking Alpha
Thu, 12/8/11 - 11:19 am
Abbott Laboratories
Warren Buffett
Eli Lilly
Merck
Pfizer
Teva Pharmaceuticals
Bristol-Myers Squibb
A Trading Strategy For 7 Biotech/Healthcare Stocks With Upcoming PDUFA Date
Seeking Alpha
Tue, 12/6/11 - 09:21 am
Alkermes
Amylin
Antares
AstraZeneca
Bristol-Myers Squibb
Merck
Eli Lilly
Drugmakers target hepatitis C
Yahoo/Investor's Business Daily
Sat, 12/3/11 - 03:57 pm
Tibotec
Bristol-Myers Squibb
JNJ
hepatitis C
TMC435
declatasvir. Ribavirin
interferon
Bristol-Myers and J&J will study a combination of 2 of their hepatitis C drug candidates
Yahoo/AP
Fri, 12/2/11 - 12:04 pm
Bristol-Myers Squibb
JNJ
hepatitis C
daclatasvir
TMC435
Two Top Biotech Plays With Safe Upside
Wed, 11/30/11 - 10:36 pm
biotech
ImmunoCellular Therapeutics
Bristol-Myers Squibb
Two Top Biotech Plays With Safe Upside
Seeking Alpha
Wed, 11/30/11 - 02:09 pm
ImmunoCellular
glioblastoma multiforme
brain cancer
Bristol-Myers Squibb
Yervoy
melanoma
Every Biotech Is for Sale
Motley Fool
Wed, 11/30/11 - 10:45 am
ONYX Pharmaceuticals
Achillion
BioSante
Indenix
Inhibitex
GSK
Bristol-Myers Squibb
Amarin
Exelixis
Winners and Losers of Roche's Avastin Woes
Motley Fool
Tue, 11/29/11 - 06:48 pm
Roche
Avastin
breast cancer
Merck
GSK
Bristol-Myers Squibb
Eli Lilly
Teva Pharmaceuticals
Dr Reddy's
Watson
Seattle Genetics
22 Hot Drugs Facing FDA Approval in 2012
TheStreet.com
Tue, 11/29/11 - 09:09 am
Amarin
AMR101
Ironwood
linaclotide
Merck
Ariad
ridaforolimus
Vivus
Qnexa
Avanafil
Amgen
Xgeva
Cell Therapeutics
pixantrone
Kalydeco
Vertex
ONYX Pharmaceuticals
Carfilzomib
Pfizer
Bristol-Myers Squibb
Eliquis
Chelsea Therapeutics
Northera
Levadex
MAP Pharmaceuticals
Roche
Curis
vismodegib
Biogen Idec
Elan
Tysabri
Amylin
Bydureon
Dapagliflozin
Uplypso
Protalix BioTherapeutics
Teva Pharmaceuticals
BioSante
Bio-T-Gel
Corlux
Corcept Therapeutics
Discovery Labs
Surfaxin
Bristol-Pfizer drug gets FDA priority review
Reuters
Tue, 11/29/11 - 08:20 am
Pfizer
FDA
Bristol-Myers Squibb
anticlotting
Eliquis
Gilead's Pharmasset Purchase Could Help Double Market Cap By 2020
Seeking Alpha
Mon, 11/28/11 - 11:38 am
Gilead
Pharmasset
M&A
hepatitis C
GSK
JNJ
Bristol-Myers Squibb
PSI-7977
Vertex
HIV
Pfizer, Bristol-Myers’ Eliquis Recommended by U.K. Cost Agency
Bloomberg
Sat, 11/26/11 - 10:33 am
Pfizer
Bristol-Myers Squibb
Eliquis
anti-clotting
Bristol-Myers Squibb Company (BMY): Today's Featured Drugs Winner
The Street
Sat, 11/19/11 - 01:23 pm
Bristol-Myers Squibb
Intellipharmaceutics: A Deep Value Opportunity In Generics And Specialty Pharmaceuticals
Seeking Alpha
Fri, 11/18/11 - 11:42 am
Intellipharmaceutics
generics
Pfizer
AstraZeneca
Novartis
Bristol-Myers Squibb
Quick review of Eliquis could lift Bristol, Pfizer
Reuters
Wed, 11/16/11 - 05:20 pm
Pfizer
Eliquis
Bristol-Myers Squibb
bloodthinner

Pages